See All Slides - tctmd.com

Slides

Presentation AHA 2018

PIONEER Trial: Angiotensin Receptor-NeprilysinInhibition in Patients Hospitalized With Acute Decompensated Heart Failure

Presenter: Eric J Velazquez

November 12, 2018

Alert-Based Computerized Decision Support to Increase Anticoagulation Prescription Prevents Stroke and Myocardial Infarction in High-Risk Hospitalized Patients with Atrial Fibrillation: A Randomized, Controlled Trial (AF-ALERT)

Presentation AHA 2018

High-Risk Hospitalized Patients with Atrial Fibrillation: A Randomized, Controlled Trial (AF-ALERT)

Presenter: Gregory Piazza

November 11, 2018

Presentation AHA 2018

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Presenter: Sotirios Tsimikas

November 11, 2018

Presentation AHA 2018

DECLARE - TIMI 58

Presenter: Stephen Wiviott

November 11, 2018

Presentation VIVA 2018

LUTONIX BTK Trial

Presenter: Jihad Mustapha

November 09, 2018

Presentation VIVA 2018

TOBA II 12-Month Data

Presenter: William Gray

November 09, 2018

Presentation VIVA 2018

1-Year Outcomes for Eluvia in Long Lesions

Presenter: William A. Gray

November 09, 2018

Presentation Cardiovascular Interventions 2018

Imaging and physiology-guided PCI without contrast administration in advanced renal failure

Presenter: Ziad A. Ali

October 26, 2018

Presentation Cardiovascular Interventions 2018

Radiation Safety for the Clinical Uses of Flouroscopy

Presenter: Paul S. Teirstein

October 26, 2018

Presentation Cardiovascular Interventions 2018

PCI Vs CABG for Multivessel and Unprotected LM Disease

Presenter: Paul S. Teirstein

October 26, 2018

Advertisement

Slides

PIONEER Trial: Angiotensin Receptor-NeprilysinInhibition in Patients Hospitalized With Acute Decompensated Heart Failure

High-Risk Hospitalized Patients with Atrial Fibrillation: A Randomized, Controlled Trial (AF-ALERT)

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

DECLARE - TIMI 58

LUTONIX BTK Trial

TOBA II 12-Month Data

1-Year Outcomes for Eluvia in Long Lesions

Imaging and physiology-guided PCI without contrast administration in advanced renal failure

Radiation Safety for the Clinical Uses of Flouroscopy

PCI Vs CABG for Multivessel and Unprotected LM Disease

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content